- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
ImmunoGen Inc+ Add to Watchlist
IMGN:US10.7250 USD 0.8950 9.10%
As of 20:10:00 ET on 12/17/2014.
Company Profile for ImmunoGen Inc (IMGN)
ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.
Key Executives for ImmunoGen Inc (IMGN)
|Daniel M Junius "Dan"President/CEO||David B Johnston "Dave"Exec VP/CFO|
|John M LambertExec VP/Chief Scientific Ofcr||Sandra E PooleSenior VP:Technical Operations|
|Charles Q Morris "Charlie"VP/Chief Development Officer||Ellie HarrisonVP/Chief Human Resources Ofcr|
|Craig BarrowsVP/Secretary/General Counsel||Peter J WilliamsVP:Business Development|
|Carol HausnerExec Dir:Investor Relations|